Revolutionary Treatment for Knee Psoriatic Arthritis Using PRP and Extracellular Vesicles: A Case Study

Knee psoriatic arthritis presents a challenging condition where inflammation from psoriasis leads to joint pain and cartilage damage. Traditional treatments often rely on steroids, which can reduce inflammation but may impair long-term joint health. This case study explores a novel approach combining Platelet Rich Plasma (PRP) enhanced with extracellular vesicles alongside Mobithron Advance injections to promote cartilage regeneration and reduce pain in a patient with knee psoriatic arthritis.

Knee joint X-ray showing cartilage regeneration after treatment

Understanding Knee Psoriatic Arthritis and Current Challenges

Psoriatic arthritis is an inflammatory arthritis associated with psoriasis, often affecting the knees. The inflammation causes joint pain, stiffness, and progressive cartilage loss, leading to osteoarthritis. Many patients receive steroid treatments to control skin and joint symptoms. While steroids reduce inflammation, long-term use can weaken cartilage and reduce the effectiveness of regenerative therapies like PRP.

PRP therapy uses a concentration of a patient’s own platelets to stimulate healing and tissue regeneration. However, in patients with prolonged steroid use, PRP’s regenerative potential may be limited. This case study investigates whether combining PRP with extracellular vesicles and Mobithron Advance can overcome these limitations and improve joint health.

Patient Background and Treatment Approach

The patient is a 59-year-old woman with a history of bilateral knee pain and skin rashes diagnosed as guttate psoriasis. Her treatment history included:

• Topical momethasone cream

• Oral prednisolone 10 mg daily

• NSAIDs for pain relief

  
  

Due to concerns about steroid effects, her steroid dose was gradually reduced, and sulfasalazine 500 mg daily was introduced as a disease-modifying antirheumatic drug (DMARD). Additionally, Mobithron Advance was started. This product combines:

• Hyaluronic acid matrix

• Undenatured type II collagen

• Boswellia serrata gum extract

  
  

After two months of this regimen, the patient received intra-articular injections in both knees consisting of PRP combined with 25 billion extracellular vesicle particles per knee.

Treatment Results and Observations

The patient was evaluated two months after the injections with standing knee X-rays and symptom assessments.

Radiological Changes

• Initial X-ray: Showed reduced joint space in both knees with osteophytes, classified as Kellgren Lawrence grade 4, indicating severe osteoarthritis.

• Follow-up X-ray: Revealed a marked increase in joint space, improving to Kellgren Lawrence grade 2, suggesting cartilage regeneration.

  
  

Symptom Improvement

• Initial pain score was 7 out of 10.

• After two months, pain reduced significantly to 2 out of 10.

  
  

These results indicate that the combination of PRP with extracellular vesicles and Mobithron Advance contributed to both structural and symptomatic improvement in the patient’s knee joints.

How the Combination Therapy Works

• PRP delivers growth factors that stimulate tissue repair and reduce inflammation.

• Extracellular vesicles are tiny particles released by cells that carry proteins, lipids, and genetic material to promote cell communication and regeneration. They enhance the effects of PRP by improving cartilage cell activity.

• Mobithron Advance supports joint health through hyaluronic acid, which lubricates the joint, type II collagen that provides building blocks for cartilage, and Boswellia serrata, a natural anti-inflammatory agent.

  
  

Together, these components create a supportive environment for cartilage repair even in patients on low-dose DMARDs and with a history of steroid use.

Practical Implications for Patients and Clinicians

This case study suggests that patients with knee psoriatic arthritis who have limited options due to steroid use might benefit from this combination therapy. Key takeaways include:

• Gradual reduction of steroids while introducing DMARDs can prepare the joint for regenerative treatments.

• Combining PRP with extracellular vesicles enhances cartilage regeneration beyond PRP alone.

• Adding Mobithron Advance supports joint lubrication and reduces inflammation naturally.

• Radiological improvements can be seen within two months, accompanied by significant pain relief.

  
  

Clinicians should consider this approach as part of a comprehensive treatment plan for psoriatic arthritis patients with knee involvement.

Future Directions and Considerations

While this case shows promising results, larger studies are needed to confirm the effectiveness and safety of combining PRP, extracellular vesicles, and Mobithron Advance in psoriatic arthritis. Monitoring long-term outcomes will help determine the durability of cartilage regeneration and symptom relief.

Patients interested in this therapy should consult their healthcare providers to discuss suitability, potential benefits, and risks. This treatment is part of an evolving field aiming to improve quality of life for those with inflammatory joint diseases.